Fig. 1. (a) Fabrication of photosensitive nanoparticles by amphiphilic dipeptide- or amino-acid- tuned self-assembly; (b) whole body fluorescence images of MCF7-tumor-bearing nude mice intravenously injected through a tail vein with FCNPs and free Ce6 (equivalent to 4.0 mg Ce6 per kilogram FCNs) at different times, black circles indicate tumor sites; (c) measured tumor size for 20 days growth (the number of mice in each group n=4)

Fig. 2. Schematic of ALA pseudopolyrotaxane prodrug micelles for photodynamic therapy

Fig. 3. (a) Synthesis of the disulfide rebridging and bioconjugation reagent 6 (azide double sulfone); (b) functionalization of SST to receive Ru-SST conjugate 8 (Ru-SST8)

Fig. 4. A concept of enzyme activatable fluorescence imaging and photodynamic therapy using a photosensitizer-conjugated gold nanorod (MMP2P-GNR)

Fig. 5. Simplified representation of a stepwise assembly process of final APMECR@MB NCs and the synergistic PDT/PTT mechanism of their action

Fig. 6. Schematic of TMB. (a) FRET mode of TMB in the closed and opened forms; (b) hairpin DNA sequence and the separation distance of each FRET pair

Fig. 7. A schematic of activatable nano-photo medicine for macrophage-targeted fluorescence imaging and subsequent photodynamic therapy

Fig. 8. Schematic illustration of the preparation of Ce6-CPT-UCNPs and concept of the light-regulated ROS-activated Ce6-CPT-UCNPs

Fig. 9. Schematic of the preparation and functional principle of AQ4N-Cu(II)-Apt Ce6-GNPs